# Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

> **NCT04061200** · PHASE4 · UNKNOWN · sponsor: **Steno Diabetes Center Copenhagen** · enrollment: 80 (estimated)

## Conditions studied

- Type 2 Diabetes With Renal Manifestations

## Interventions

- **DRUG:** Semaglutide, 1.34 mg/mL
- **OTHER:** Placebo, 1,34 mg/mL
- **DRUG:** Empagliflozin 25 MG

## Key facts

- **NCT ID:** NCT04061200
- **Lead sponsor:** Steno Diabetes Center Copenhagen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-08-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2019-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04061200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04061200, "Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04061200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*